Multiple system atrophy

This Phase 2 trial tests the safety and effectiveness of YA-101, an oral drug, in 75 people with multiple system atrophy (MSA), a rare and progressive brain disorder. Participants will receive either YA-101 or a placebo twice daily for several weeks. The study will monitor side e…

This Phase 3 trial tests an experimental drug called amlenetug in 401 people with multiple system atrophy (MSA), a rare and serious brain disorder. The goal is to see if the drug can slow the worsening of symptoms and improve survival. Participants receive either the drug or a pl…

This study tests an experimental drug called ONO-2808 in people with multiple system atrophy (MSA), a rare and serious brain disease. About 92 participants will receive either the drug or a placebo daily for up to 80 weeks. The goal is to see if the drug is safe and might help co…

This Phase 2 trial tests whether a patient's own stem cells, injected into the spinal fluid, can slow the progression of multiple system atrophy (MSA), a rare and fatal brain disease. The study involves 71 adults aged 30-70 with early-stage MSA. Researchers will measure changes i…

This study tests an experimental drug called Lu AF82422 in 64 people with multiple system atrophy (MSA), a rare and serious brain disease. The goal is to see if the drug can slow down the worsening of symptoms like movement problems and daily living difficulties. Participants rec…

This study tests whether a person's own stem cells can be safely injected into the spinal fluid to treat multiple system atrophy (MSA), a rare and serious brain disease. About 30 adults aged 30-80 with MSA will receive the treatment. The main goal is to check for side effects, an…

This early-stage trial tests a gene therapy called AAV2-GDNF for multiple system atrophy (MSA), a rare and serious brain disorder. Nine adults with MSA will receive either the gene therapy or a sham surgery. The main goal is to check safety, but researchers will also look for any…

This study tests an AI tool called AIDP that analyzes MRI scans to help diagnose Parkinson's disease and two similar conditions (MSA and PSP). Researchers at 21 sites will compare the AI's diagnosis to that of movement disorder specialists. The goal is to see if the tool can impr…

This study tests whether a home-based telenursing program, led by a specialist nurse, can improve quality of life and reduce complications like falls for people with atypical parkinsonism (MSA or PSP). About 164 participants will receive proactive and reactive remote monitoring a…

This study looks at whether online community support and telemedicine can improve quality of life for people with Parkinson's disease, Lewy body dementia, and related conditions, as well as their caregivers. About 632 participants will receive palliative care training for their d…

This study is testing whether a daily supplement made from baker's yeast can improve digestion and reduce gut symptoms in healthy adults aged 50 to 99. Participants take 15 grams of the supplement each day and report any changes in how their stomach feels. The goal is to see if t…

This phase 3 study tests a drug called ampreloxetine for people with multiple system atrophy (MSA) who experience dizziness and fainting due to low blood pressure when standing. About 102 adults with MSA will take the drug for 20 weeks, then some will switch to placebo to see if …

This study aims to find early markers of Parkinson's disease, multiple system atrophy, and Lewy body dementia by analyzing samples from the nose, blood, and urine. Researchers will compare results from 180 people with these conditions and healthy volunteers. The goal is to improv…

This study follows 20,000 healthy Chinese adults aged 40-75 living at various altitudes to see if chronic low oxygen levels increase the risk of multiple system atrophy (MSA), a rare and fatal brain disease. Participants undergo checkups and overnight oxygen monitoring, then are …

This study investigates whether people with neurodegenerative diseases—like Alzheimer's, Parkinson's, or ALS—show changes in behavior, social circumstances, or health before and after their diagnosis. Researchers will compare the records of over 61,000 patients with those of matc…

This study examines walking patterns in people with Parkinson's disease and similar neurological conditions, as well as healthy volunteers. Researchers aim to identify unique 'gait signatures'—speed-dependent measures of walking—that could help distinguish between different disor…

This study aims to identify biomarkers—biological clues in the body—that can help distinguish between Parkinson's disease and similar conditions like progressive supranuclear palsy and multiple system atrophy. Researchers will follow people with early-stage parkinsonism and healt…

This study enrolls 500 adults with a sleep condition called REM sleep behavior disorder (RBD), which often leads to Parkinson's disease or related brain disorders. Researchers will track symptoms like thinking, movement, and smell to develop a rating scale. The goal is to prepare…

This study looks at how the body's automatic nervous system controls blood flow in abdominal veins and how that might lead to high blood pressure in people with Multiple System Atrophy (MSA). Researchers will measure vein responses in about 16 participants aged 40-80 who have MSA…

This study follows 90 people with Multiple System Atrophy (MSA), a rare brain disease, for 12 months. Researchers measure changes in movement, thinking, brain scans, and blood markers to better understand how the disease progresses. The goal is to gather information, not to test …

This study aims to learn more about diseases that affect the brain, such as Parkinson's disease and different types of dementia. Researchers will follow 500 adults with symptoms of these conditions over time, using brain scans and genetic tests to see how the diseases progress. T…

This study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.